Exosome Therapeutics Pipeline research 2024 [Yahoo! Finance]
Celularity Inc. - Class A (CELU)
Company Research
Source: Yahoo! Finance
An array of drugs is currently moving through various stages of clinical development, bringing hope and anticipation to numerous patient populations. New findings have unveiled that these novel exosome-based therapies demonstrate the capability to transport therapeutic agents, such as proteins, RNA, and even gene-modifying tools, to specific sites within the body. Innovations like CAP-1002, AGLE-102, ILB-202, and ExoAAV embody the forefront of this medical revolution, with clinical trials yielding promising outcomes in areas such as Duchenne muscular dystrophy, inflammatory diseases, dystrophic epidermolysis bullosa, and even genetic conditions such as phenylketonuria. Strategic Collaborations and Assessments Collaborative efforts across the industry, along with rigorous evaluation and therapeutic assessment of these emerging drugs, are key contributors to the advancement and refinement of exosome therapies. Research and development activities continue to gain momentum, fueled by
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- 5 Startup Opportunities In Anti-Ageing [Forbes]Forbes
- Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing [Seeking Alpha]Seeking Alpha
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing [Yahoo! Finance]Yahoo! Finance
CELU
Earnings
- 1/2/24 - Miss
CELU
Sec Filings
- 5/24/24 - Form 8-K
- 5/21/24 - Form 8-K
- 5/15/24 - Form NT
- CELU's page on the SEC website